Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Considering synergism between docetaxel (D), capecitabine (X), and oxaliplatin (O) and
favourable toxicity profile of oxaliplatin over cisplatin, it is to be expected that
combination of docetaxel, capecitabine, and oxaliplatin (DXO) will be more effective than
other regimens and feasible in advanced gastric cancer. DXO regimen can be also easily
administered on out-patient setting. However, so far, DXO combination has not been tried in
advanced gastric cancer. The investigators will determine maximum tolerated dose of DXO
regimen in this phase I study.